TEM8 specific T cells target the tumor cells and tumor-associated vasculature in triple negative breast cancer

Byrd, Tiara; Fousek, Kristen; Pignata, Antonella; Wakefield, Amanda; Croix, Brad St.; Fletcher, Bradley S.; Hegde, Meenakshi; Ahmed, Nabil

doi:10.1186/2051-1426-2-s3-p7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Tumor Endothelial Marker (Tem8)1

Chimeric Antigen Receptors T-cells1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2020

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TEM8 is a collagen-binding cell surface glycoprotein that promotes the migration of endothelial cells (110). TEM8 is overexpressed on the surface of primary TNBC cells and in the vasculature of solid tumors.…”

Section: Tumor Endothelial Marker (Tem8)mentioning

confidence: 99%

Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

Dees

Ganesan

Singh

et al. 2020

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Tumor Endothelial Marker (Tem8)mentioning

confidence: 99%

Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

Dees

Ganesan

Singh

et al. 2020

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Tumor endothelium marker 8 (TEM8) is a tumor restricted antigen expressed in TNBC. TEM8specific CAR T-cells have been developed and shown promising results as an anti-TNBC modality (Fousek et al, 2014). Moreover, other highly expressed potential targets in TNBC such as FRα and brachyury may be used for CAR T-cell based therapies development (June, O'connor, Kawalekar, Ghassemi, & Milone, 2018 , 2013).…”

Section: Chimeric Antigen Receptors T-cellsmentioning

confidence: 99%

Single peptides and combination modalities for triple negative breast cancer

Razazan

Behravan

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Unlike other types of breast cancers (BCs), no specific therapeutic targets have been established for triple negative breast cancer (TNBC). Therefore, chemotherapy and radiotherapy are the only available adjuvant therapeutic choices for TNBC. New emerging reports show that TNBC is associated with higher numbers of intratumoral tumor infiltrating lymphocytes. This is indicative of host anti-TNBC immune surveillance and suggesting that immunotherapy can be considered as a therapeutic approach for TNBC management. Recent progress in molecular mechanisms of tumor-immune system interaction and cancer vaccine development studies, fast discoveries and FDA approvals of immune checkpoint inhibitors, chimeric antigen receptor T-cells, and oncolytic virotherapy have significantly attracted attention and research directions toward the immunotherapeutic approach to TNBC. Here in this review different aspects of TNBC immunotherapies including the host immune system-tumor interactions, the tumor microenvironment, the relevant molecular targets for immunotherapy, and clinical trials in the field are discussed.

show abstract

TEM8 specific T cells target the tumor cells and tumor-associated vasculature in triple negative breast cancer

Cited by 2 publications

References 2 publications

Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

Single peptides and combination modalities for triple negative breast cancer

Contact Info

Product

Resources

About